



(11) **EP 3 759 088 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(48) Corrigendum issued on:
08.03.2023 Bulletin 2023/10

(45) Date of publication and mention
of the grant of the patent:
25.01.2023 Bulletin 2023/04

(21) Application number: **19710473.0**

(22) Date of filing: **26.02.2019**

(51) International Patent Classification (IPC):
C07D 401/04 ^(2006.01) **C07D 403/04** ^(2006.01)
C07D 405/04 ^(2006.01) **C07D 409/04** ^(2006.01)
C07D 417/04 ^(2006.01) **A61K 31/53** ^(2006.01)
C07D 251/34 ^(2006.01) **A61P 25/00** ^(2006.01)
A61P 25/24 ^(2006.01) **A61P 25/16** ^(2006.01)
A61P 25/28 ^(2006.01)

(52) Cooperative Patent Classification (CPC):
C07D 251/34; A61P 25/00; A61P 25/16;
A61P 25/24; A61P 25/28; C07D 401/04;
C07D 403/04; C07D 405/04; C07D 409/04;
C07D 417/04

(86) International application number:
PCT/GB2019/050523

(87) International publication number:
WO 2019/162702 (29.08.2019 Gazette 2019/35)

(54) **TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS**

TRIAZINDERIVATE ZUR BEHANDLUNG VON ERKRANKUNGEN IM ZUSAMMENHANG MIT
NEUROTROPHINEN

DÉRIVÉS DE TRIAZINE POUR LE TRAITEMENT DE MALADIES ASSOCIÉES À DES
NEUROTROPHINES

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: **26.02.2018 SE 1850217**
28.06.2018 GB 201810667

(43) Date of publication of application:
06.01.2021 Bulletin 2021/01

(73) Proprietor: **AlzeCure Pharma AB**
141 57 Huddinge (SE)

(72) Inventors:
• **NORDVALL, Gunnar**
144 61 Rönninge (SE)

• **FORSELL, Pontus**
141 40 Huddinge (SE)

(74) Representative: **Potter Clarkson**
Chapel Quarter
Chapel Bar
Nottingham NG1 6HQ (GB)

(56) References cited:
EP-A1- 0 279 219 EP-A2- 0 081 142
WO-A1-2018/115891 DE-A1- 3 408 768
US-A- 3 933 814 US-A- 3 966 725

• **JUSTIN J. BAILEY ET AL: "Tropomyosin receptor
kinase inhibitors: an updated patent review for
2010-2016 - Part I", EXPERT OPINION ON
THERAPEUTIC PATENTS, vol. 27, no. 6, 8 March
2017 (2017-03-08), pages 733-751, XP55453922,
ISSN: 1354-3776, DOI:
10.1080/13543776.2017.1297796**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).